TWI860474B - 冠狀病毒疫苗 - Google Patents

冠狀病毒疫苗 Download PDF

Info

Publication number
TWI860474B
TWI860474B TW110113684A TW110113684A TWI860474B TW I860474 B TWI860474 B TW I860474B TW 110113684 A TW110113684 A TW 110113684A TW 110113684 A TW110113684 A TW 110113684A TW I860474 B TWI860474 B TW I860474B
Authority
TW
Taiwan
Prior art keywords
composition
rna
sars
cov
dose
Prior art date
Application number
TW110113684A
Other languages
English (en)
Chinese (zh)
Other versions
TW202206096A (zh
Inventor
烏古爾 沙興
歐普特金 古勒
安卓亞斯 古恩
亞歷山大 穆科
安尼堤 沃格
科斯汀 華爾茲
頌雅 維特策
史黛芬妮 海恩
奧茲廉 圖雷西
Original Assignee
德商拜恩迪克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商拜恩迪克公司 filed Critical 德商拜恩迪克公司
Publication of TW202206096A publication Critical patent/TW202206096A/zh
Application granted granted Critical
Publication of TWI860474B publication Critical patent/TWI860474B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/18011—Comoviridae
    • C12N2770/18071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
TW110113684A 2020-04-22 2021-04-16 冠狀病毒疫苗 TWI860474B (zh)

Applications Claiming Priority (46)

Application Number Priority Date Filing Date Title
EP2020061239 2020-04-22
WOPCT/EP2020/061239 2020-04-22
EP2020066968 2020-06-18
WOPCT/EP2020/066968 2020-06-18
WOPCT/EP2020/068174 2020-06-26
EP2020068174 2020-06-26
WOPCT/EP2020/069805 2020-07-13
EP2020069805 2020-07-13
WOPCT/EP2020/071733 2020-07-31
EP2020071733 2020-07-31
WOPCT/EP2020/071839 2020-08-03
EP2020071839 2020-08-03
WOPCT/EP2020/073668 2020-08-24
EP2020073668 2020-08-24
EP2020081544 2020-11-09
WOPCT/EP2020/081544 2020-11-09
WOPCT/EP2020/081981 2020-11-12
EP2020081981 2020-11-12
EP2020082601 2020-11-18
WOPCT/EP2020/082601 2020-11-18
WOPCT/EP2020/082989 2020-11-20
EP2020082989 2020-11-20
WOPCT/EP2020/083435 2020-11-25
EP2020083435 2020-11-25
WOPCT/EP2020/084342 2020-12-02
EP2020084342 2020-12-02
WOPCT/EP2020/085145 2020-12-08
EP2020085145 2020-12-08
EP2020085653 2020-12-10
WOPCT/EP2020/085653 2020-12-10
EP2020087844 2020-12-23
WOPCT/EP2020/087844 2020-12-23
WOPCT/EP2021/050027 2021-01-04
EP2021050027 2021-01-04
WOPCT/EP2021/050874 2021-01-15
EP2021050875 2021-01-15
WOPCT/EP2021/050875 2021-01-15
EP2021050874 2021-01-15
WOPCT/EP2021/051772 2021-01-26
EP2021051772 2021-01-26
WOPCT/EP2021/052572 2021-02-03
EP2021052572 2021-02-03
WOPCT/EP2021/052716 2021-02-04
EP2021052716 2021-02-04
WOPCT/EP2021/054622 2021-02-24
EP2021054622 2021-02-24

Publications (2)

Publication Number Publication Date
TW202206096A TW202206096A (zh) 2022-02-16
TWI860474B true TWI860474B (zh) 2024-11-01

Family

ID=75438688

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110113684A TWI860474B (zh) 2020-04-22 2021-04-16 冠狀病毒疫苗
TW113143512A TW202508622A (zh) 2020-04-22 2021-04-16 冠狀病毒疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113143512A TW202508622A (zh) 2020-04-22 2021-04-16 冠狀病毒疫苗

Country Status (14)

Country Link
US (8) US11547673B1 (enExample)
EP (6) EP3901261A1 (enExample)
JP (5) JP2021185136A (enExample)
KR (2) KR102813425B1 (enExample)
CN (7) CN113521269A (enExample)
AU (3) AU2021261471B2 (enExample)
BR (2) BR112022019781A2 (enExample)
CA (2) CA3174215A1 (enExample)
GB (3) GB2594365B (enExample)
IL (5) IL297419B2 (enExample)
MX (4) MX2022013254A (enExample)
TW (2) TWI860474B (enExample)
WO (2) WO2021213924A1 (enExample)
ZA (2) ZA202210526B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
HUE064227T2 (hu) 2015-09-21 2024-02-28 Trilink Biotechnologies Llc Módszer 5'-sapkával ellátott rns-ek szintetizálására
EA202190688A1 (ru) 2018-10-09 2021-06-07 Дзе Юниверсити Оф Бритиш Коламбиа Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы
EP3947406A4 (en) 2019-04-05 2022-12-28 Academia Sinica SIALIDASE RESISTANT SACCHARIDE, METHOD FOR PRODUCTION AND USE
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CN113527510A (zh) * 2020-04-22 2021-10-22 上海交通大学 融合蛋白分子及其制备方法和用途
AU2021261471B2 (en) * 2020-04-22 2024-10-24 BioNTech SE Coronavirus vaccine
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
GB202017649D0 (en) * 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
EP4244630A4 (en) * 2020-11-12 2025-05-21 Tscan Therapeutics, Inc. Sars-cov-2 immunodominant peptide constructs and uses thereof
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
BR112023012303A2 (pt) 2020-12-22 2024-02-15 CureVac SE Vacina de rna contra variantes de sars-cov-2
WO2022162027A2 (en) * 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022215036A1 (en) 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
EP4334944A1 (en) 2021-05-04 2024-03-13 BioNTech SE Immunogen selection
CA3235180A1 (en) * 2021-10-21 2023-04-27 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116200403A (zh) * 2021-11-30 2023-06-02 石药集团巨石生物制药有限公司 预防突变株的新型冠状病毒mRNA疫苗
KR20240134898A (ko) 2021-12-16 2024-09-10 에이치씨이엠엠 논프로핏 케이에프티. 백신 제제
KR20230095025A (ko) * 2021-12-20 2023-06-28 아이진 주식회사 변이 SARS-CoV-2 백신 조성물 및 이의 용도
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
EP4475882A1 (en) * 2022-02-09 2024-12-18 ModernaTX, Inc. Mucosal administration methods and formulations
WO2023152188A1 (en) * 2022-02-11 2023-08-17 Attana Ab Analytical method
CN116768987A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
WO2023172547A1 (en) * 2022-03-11 2023-09-14 National Health Research Institutes Nucleic acid-lipid nanoparticle and method using the same
EP4496578A1 (en) * 2022-03-22 2025-01-29 Osivax Mrna vaccine compositions and their use
WO2023202711A1 (zh) * 2022-04-22 2023-10-26 仁景(苏州)生物科技有限公司 一种基于新型冠状病毒的mRNA疫苗
KR20250007577A (ko) 2022-04-27 2025-01-14 상하이 레제네리드 테라피즈 컴퍼니 리미티드 핵산 작제물 및 이의 응용
CN114989308B (zh) * 2022-05-12 2023-04-04 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
CN119563028A (zh) 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
AU2023268051A1 (en) 2022-05-13 2025-01-02 BioNTech SE Rna compositions targeting hiv
WO2023220842A1 (en) * 2022-05-19 2023-11-23 Shenzhen Genius Biotech Service Co.,Ltd. A fusion protein as a subunit vaccine immunogen against sars-cov-2 and the preparation thereof
WO2023228116A1 (en) * 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
AU2023275780A1 (en) 2022-05-25 2024-12-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
CN114934056B (zh) * 2022-06-24 2023-10-20 仁景(苏州)生物科技有限公司 一种基于新型冠状病毒奥密克戎突变株的mRNA疫苗
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
EP4560021A1 (en) * 2022-07-19 2025-05-28 Shenzhen Shenxin Biotechnology Co., Ltd. Mrna for sars-cov-2 s protein and use thereof
CN117414418A (zh) * 2022-07-19 2024-01-19 深圳深信生物科技有限公司 一种新型冠状病毒变异株的mRNA疫苗及其应用
WO2024026287A2 (en) * 2022-07-25 2024-02-01 University Of Utah Research Foundation Synthesis of substoichiometric chemically modified mrnas by in vitro transcription
CN115716866A (zh) * 2022-09-30 2023-02-28 珠海丽凡达生物技术有限公司 新型冠状病毒疫苗及其制备方法和应用
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
JP2025533111A (ja) 2022-10-04 2025-10-03 ビオンテック・ソシエタス・エウロパエア Ｒｎａコンストラクト及びその使用
AU2023357320A1 (en) 2022-10-06 2025-04-17 BioNTech SE Rna compositions targeting claudin-18.2
EP4604995A1 (en) 2022-10-17 2025-08-27 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
CN118045169A (zh) * 2022-11-10 2024-05-17 中国科学院化学研究所 脂质-带电分子偶联物、可吸入式脂质纳米颗粒及其制备方法和应用
WO2024109866A1 (zh) 2022-11-24 2024-05-30 苏州艾博生物科技有限公司 提高蛋白表达量的utr分子
AU2023396545A1 (en) * 2022-12-16 2025-07-17 Shenzhen Shenxin Biotechnology Co., Ltd. Utr for improving translation efficiency and/or stability of rna molecule and use thereof
EP4642797A1 (en) 2022-12-28 2025-11-05 BioNTech SE Rna compositions targeting hiv
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
WO2024170652A1 (en) 2023-02-14 2024-08-22 Radiovaxx Gmbh Drug and treatment method
CN116410992A (zh) * 2023-03-10 2023-07-11 北京新合睿恩生物医疗科技有限公司 预防和/或治疗新型冠状病毒的mRNA、疫苗及其制备方法和应用
CN115998714B (zh) * 2023-03-20 2023-06-30 威瑞生物科技(昆明)有限责任公司 一种脂质纳米颗粒、递送系统及递送系统的制备方法
WO2024197098A2 (en) * 2023-03-20 2024-09-26 Cartesian Therapeutics, Inc. Local conditioning of lymph nodes with diffusion-limited particles for in vivo car therapy
AU2024252371A1 (en) 2023-04-08 2025-10-09 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
TW202502301A (zh) 2023-04-08 2025-01-16 磐石醫藥生技股份有限公司 透過聚合物囊泡進行標的遞送之方法及組合物
WO2024216212A1 (en) * 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2024222737A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 工程化的mRNA及其用途
CN119731324A (zh) * 2023-05-30 2025-03-28 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗
US20250135006A1 (en) 2023-07-07 2025-05-01 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
WO2025017029A1 (en) * 2023-07-17 2025-01-23 Eleven Therapeutics Ltd Non-natural building blocks for enhanced translation and stability of mrna
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
CN117224662B (zh) * 2023-08-24 2025-05-16 北京悦康科创医药科技股份有限公司 测定多价新冠mRNA疫苗各组分含量的方法
WO2025054401A2 (en) * 2023-09-06 2025-03-13 Trilink Biotechnologies, Llc Cap analogs and methods of use thereof
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025078604A1 (en) * 2023-10-13 2025-04-17 Smartcella Solutions Ab Methods and compositions for delivery of unmodified mrna constructs using mesenchymal stem cells
WO2025179238A2 (en) 2024-02-23 2025-08-28 BioNTech SE Coronavirus vaccine
CN118389495B (zh) * 2024-06-24 2024-10-01 北京悦康科创医药科技股份有限公司 一种核糖修饰的加帽类似物及其应用
KR102832944B1 (ko) 2024-12-27 2025-07-15 대한민국 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070626A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Respiratory virus vaccines

Family Cites Families (366)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898278A (en) 1986-12-05 1990-02-06 Nalge Company Storage container
JPH10113117A (ja) 1996-10-11 1998-05-06 Tomoji Tanaka 保冷箱
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
US6965041B1 (en) 1999-03-24 2005-11-15 The United States Of America As Represented By The Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US6381981B1 (en) 2001-05-02 2002-05-07 Advanced Tissue Sciences, Inc. Container for shipping and storing frozen products
ATE464317T1 (de) 2001-06-05 2010-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt für die gentherapie
US20030082357A1 (en) 2001-09-05 2003-05-01 Cem Gokay Multi-layer core for vacuum insulation panel and insulated container including vacuum insulation panel
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
WO2004002415A2 (en) 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
JP4509999B2 (ja) * 2003-02-17 2010-07-21 ブルクハルト，ペーター 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
US7897744B2 (en) 2003-04-28 2011-03-01 The Public Health Agency Of Canada SARS virus nucleotide and amino acid sequences and uses thereof
CN1820020B (zh) 2003-05-06 2010-04-28 技术持有有限公司 Sars-冠状病毒病毒样颗粒以及应用方法
CN1788502B (zh) 2003-06-10 2011-05-18 诺基亚有限公司 用于使移动台在自动传输与调度传输之间切换的方法和设备
US7320857B2 (en) 2003-06-18 2008-01-22 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
CN1977045A (zh) 2003-08-04 2007-06-06 马萨诸塞大学 Sars核酸,蛋白质,疫苗以及它们的用途
TW200515917A (en) * 2003-09-15 2005-05-16 Us Government Methods and compositions for the generation of a protective immune response against SARS-COV
US7129042B2 (en) 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
ES2396127T3 (es) 2003-12-02 2013-02-19 Institut Pasteur Uso de proteinas y peptidos codificados por el genoma de una nueva cepa de coronavirus asociado al SRAS
US20050178142A1 (en) 2004-02-17 2005-08-18 Perry Ralph J. 96 hour duration insulated cryo-pack for maintaining -40 degree fahrenheit
CA2568838A1 (en) 2004-06-04 2005-12-15 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
US7870748B2 (en) 2005-02-25 2011-01-18 Byrne Kathleen H Method for controlled rate freezing and long term cryogenic storage
WO2006138005A2 (en) 2005-05-10 2006-12-28 Monsanto Technology, Llc Genes and uses for plant improvement
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CA2659301A1 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
US8865398B2 (en) 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
CN104072561B (zh) 2007-06-19 2017-12-22 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
AU2015210364B2 (en) 2008-10-09 2017-03-09 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
GB0818663D0 (en) * 2008-10-10 2008-11-19 Ark Therapeutics Ltd Gene regulation and its use in therapy
DK3067064T3 (da) 2008-12-09 2020-06-08 Novavax Inc Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
RS57314B1 (sr) 2009-12-01 2018-08-31 Translate Bio Inc Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
AU2015210336B2 (en) 2010-08-17 2017-05-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
DK4008357T3 (da) * 2010-08-31 2023-02-20 Glaxosmithkline Biologicals Sa Små liposomer til afgivelse af immunogen-kodende RNA
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CA2835428A1 (en) 2011-05-17 2012-11-22 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
LT2717893T (lt) 2011-06-08 2019-08-12 Translate Bio, Inc. Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
EP2755693A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP2791364A4 (en) 2011-12-14 2015-11-11 Moderna Therapeutics Inc PROCESS FOR RESPONSE TO A BIOLOGICAL THREAT
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
RU2014129863A (ru) 2011-12-21 2016-02-10 Модерна Терапьютикс, Инк. Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP3260541B1 (en) 2012-03-27 2019-05-15 CureVac AG Artificial nucleic acid molecules for improved protein or peptide expression
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US20150050354A1 (en) * 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
AU2014220957A1 (en) 2013-02-22 2015-07-30 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
EP3292873B1 (en) 2013-02-22 2019-05-01 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014152659A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
EP3467108B1 (en) 2013-03-14 2024-05-22 Translate Bio, Inc. Methods for purification of messenger rna
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
WO2014172045A1 (en) 2013-03-15 2014-10-23 The University Of British Columbia Lipid nanoparticles for transfection and related methods
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
EP3036330B1 (en) 2013-08-21 2018-09-12 CureVac AG Method for increasing expression of rna-encoded proteins
KR102354389B1 (ko) 2013-08-21 2022-01-20 큐어백 아게 Rna―암호화된 단백질의 발현을 증가시키는 방법
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US20160243221A1 (en) 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3542802A1 (en) 2013-11-01 2019-09-25 CureVac AG Modified rna with decreased immunostimulatory properties
CN105934441A (zh) * 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
WO2015101416A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Methods for rna analysis
EP3540060A1 (en) 2013-12-30 2019-09-18 CureVac AG Methods for rna analysis
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
HUE069802T2 (hu) 2014-04-23 2025-04-28 Modernatx Inc Nukleinsav vakcinák
DK3636742T3 (da) 2014-04-25 2025-11-24 Translate Bio Inc Fremgangsmåder til oprensning af messenger-rna
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
ES2931832T3 (es) 2014-06-25 2023-01-03 Acuitas Therapeutics Inc Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
CA2955375A1 (en) 2014-07-17 2016-01-21 Modernatx, Inc. Terminal modifications of polynucleotides
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016077123A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Multiparametric nucleic acid optimization
DK4023755T5 (da) 2014-12-12 2024-07-29 CureVac SE Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
EP3298142B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
DE202016009003U1 (de) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017019935A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Multimeric mrna
DK4155409T5 (da) 2015-08-10 2024-07-22 Curevac Mfg Gmbh Fremgangsmåde til at øge replikationen af et cirkulært dna-molekyle
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP4029522B1 (en) 2015-08-28 2025-08-13 BioNTech SE Method for reducing immunogenicity of rna
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
ES2969082T3 (es) 2015-09-17 2024-05-16 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
HUE064227T2 (hu) * 2015-09-21 2024-02-28 Trilink Biotechnologies Llc Módszer 5'-sapkával ellátott rns-ek szintetizálására
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
CA3001014A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
KR20180096591A (ko) 2015-10-22 2018-08-29 모더나티엑스, 인크. 광범위 인플루엔자 바이러스 백신
BR112018008102A2 (pt) 2015-10-22 2018-11-06 Modernatx Inc vacina de vírus sincicial respiratório
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EA201890999A1 (ru) 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против вируса простого герпеса
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
CA3003090A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
PT3368507T (pt) 2015-10-28 2023-02-07 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
PT3386484T (pt) 2015-12-10 2022-08-01 Modernatx Inc Composições e métodos para entrega de agentes terapêuticos
EP3390630B1 (en) 2015-12-17 2025-01-22 ModernaTX, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
GB2546257A (en) 2016-01-08 2017-07-19 The Wool Packaging Company Ltd Temperature controlled packaging and transportation method
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017162266A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2017201352A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
KR20230074598A (ko) 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
AU2017268396B2 (en) 2016-05-18 2023-05-18 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
MA45032A (fr) 2016-05-18 2019-03-27 Fundacion Para La Investig Medica Aplicada Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
US20190382774A1 (en) 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
ES2973443T3 (es) 2016-05-18 2024-06-20 Modernatx Inc Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
JP2019525901A (ja) 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
GB201611050D0 (en) 2016-06-24 2016-08-10 Softbox Systems Ltd A passive temperature control system for transport and storage containers
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
US10487105B2 (en) * 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018078053A1 (en) 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
WO2018081462A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Methods and compositions for rna mapping
EP3532103B1 (en) * 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
MX2019004810A (es) 2016-10-26 2019-10-15 Modernatx Inc Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos.
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
WO2018144778A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Polynucleotide secondary structure
EP3576751A4 (en) 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
SG11201907846VA (en) * 2017-02-28 2019-09-27 Sanofi Sa Therapeutic rna
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
ES3020935T3 (en) 2017-03-15 2025-05-23 Modernatx Inc Lipid nanoparticle formulation
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
ES2940259T3 (es) 2017-03-15 2023-05-04 Modernatx Inc Compuesto y composiciones para la administración intracelular de agentes terapéuticos
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US20200038499A1 (en) 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
CN107033250B (zh) 2017-05-23 2020-01-21 山东省农业科学院奶牛研究中心 牛冠状病毒重组多表位抗原及其应用
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
WO2019035998A1 (en) 2017-08-17 2019-02-21 Modernatx, Inc. SYSTEMS WITH CONTROL AND REGULATION OF FLUID PATH
EP3668971B8 (en) * 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
GB201718660D0 (en) 2017-11-10 2017-12-27 Ucl Business Plc Improved liposome for mRNA delivery to cells
JP2021504445A (ja) 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
CA3106812A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Homology-directed repair template design and delivery to edit hemoglobin-related mutations
WO2019232097A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
KR20210038886A (ko) 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
CA3111836A1 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
JP7526168B2 (ja) 2018-09-19 2024-07-31 モデルナティエックス インコーポレイテッド Ｐｅｇ脂質及びそれらの使用
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3860972A1 (en) 2018-10-02 2021-08-11 Intellia Therapeutics, Inc. Ionizable amine lipids
KR102076917B1 (ko) * 2018-10-25 2020-02-13 연세대학교 산학협력단 자가조립 나노 입자를 제조하기 위한 유전자 재조합 발현 벡터 시스템 및 이를 이용하는 방법
CA3118947A1 (en) 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
CN111200358B (zh) 2018-11-19 2021-09-03 广东美的白色家电技术创新中心有限公司 抑制冷媒散热器的电磁干扰的系统及家用电器
TW202515617A (zh) 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
MX2021009245A (es) 2019-01-31 2021-11-12 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
EP3927821A4 (en) 2019-02-20 2023-01-25 ModernaTX, Inc. RNA POLYMERASE VARIANTS FOR CO-STRANSCRIPTION CAPTING
JP2022526089A (ja) 2019-03-11 2022-05-23 モデルナティエックス インコーポレイテッド 流加バッチインビトロ転写プロセス
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
AU2020245537A1 (en) * 2019-03-25 2021-11-18 Ohio State Innovation Foundation Engineered mRNA sequences and uses thereof
US20220236253A1 (en) 2019-05-31 2022-07-28 Modernatx, Inc. Expanded t cell assay
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN110378000B (zh) 2019-07-11 2020-11-24 上海理工大学 基于强度场的结构静强度设计方法
BR112022002548A2 (pt) 2019-08-14 2022-06-14 Modernatx Inc Processos para purificar produtos a jusante de transcrição in vitro
LT4013385T (lt) 2019-08-14 2024-09-25 Acuitas Therapeutics, Inc. Patobulintos lipidų nanodalelės nukleorūgščių įvedimui
JP2022547313A (ja) 2019-09-11 2022-11-11 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
US20220340736A1 (en) 2019-09-16 2022-10-27 Aalto University Foundation Sr Homogeneous fiber product based on bio-oil and/or water and method for their production
JP2022548957A (ja) 2019-09-19 2022-11-22 モデルナティエックス インコーポレイテッド キャップガイド及びｒｎａマッピングのためのその使用方法
GB201915905D0 (en) 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
US20210217484A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Variational autoencoder for biological sequence generation
WO2021147025A1 (en) 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
TW202142555A (zh) 2020-01-27 2021-11-16 美商諾瓦瓦克斯股份有限公司 冠狀病毒疫苗配製品
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
JP2023511633A (ja) * 2020-01-28 2023-03-20 モデルナティエックス インコーポレイテッド コロナウイルスｒｎａワクチン
CN115103682A (zh) 2020-01-30 2022-09-23 摩登纳特斯有限公司 呼吸道病毒免疫组合物
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
WO2021155760A1 (zh) 2020-02-03 2021-08-12 康希诺生物股份公司 用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用
MX2022009460A (es) * 2020-02-04 2022-12-16 Curevac Ag Vacuna contra el coronavirus.
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
EP4101864B1 (en) 2020-02-05 2025-10-22 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Polypeptide, and preparation method therefor and use thereof
MX2022009707A (es) 2020-02-07 2022-09-07 Modernatx Inc Vacunas de dominio de arnm contra el sars-cov-2.
AU2021216443A1 (en) 2020-02-07 2022-09-08 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
BR112022015707A2 (pt) 2020-02-10 2022-09-27 Inst Microbiology Cas Antígenos de beta-coronavírus, métodos de preparação e usos dos mesmos
BR112022015628A2 (pt) * 2020-02-11 2022-09-27 Us Health Vacina de sars-cov-2
WO2021163371A1 (en) 2020-02-12 2021-08-19 La Jolla Institute For Immunology Coronavirus t cell epitopes and uses thereof
WO2021160346A1 (en) 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
AU2021218985A1 (en) 2020-02-13 2022-08-25 Institut Pasteur Measles-vectored COVID-19 immunogenic compositions and vaccines
CN113186203B (zh) 2020-02-13 2022-12-30 斯微(上海)生物科技股份有限公司 治疗或者预防冠状病毒病的疫苗试剂
CA3167498A1 (en) 2020-02-14 2021-08-19 Anne De Groot T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19
GB2594683A (en) 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine
CN111303254A (zh) 2020-02-20 2020-06-19 北京新创生物工程有限公司 新型冠状病毒（SARS-CoV-2）抗原检测试剂盒
CN110951756B (zh) 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950B (zh) 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
US20220347289A1 (en) 2020-02-23 2022-11-03 Guangzhou N Biomed Ltd. Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
CN112300251B (zh) 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
CN111218458B (zh) 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
EP4114463A4 (en) 2020-03-01 2023-09-06 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
US20230346916A1 (en) 2020-03-05 2023-11-02 New York Blood Center, Inc. Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
US12269846B2 (en) 2020-03-05 2025-04-08 Swey-Shen Chen CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
PE20221758A1 (es) 2020-03-13 2022-11-11 Univ Oxford Innovation Ltd Composiciones y metodos para la induccion de una respuesta inmune
CN111218459B (zh) 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
WO2021188906A1 (en) 2020-03-19 2021-09-23 Nature's Toolbox, Inc. Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same
CN111088283B (zh) 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
US20230141371A1 (en) 2020-03-20 2023-05-11 Biontech Us Inc. Coronavirus vaccines and methods of use
CN111560074B (zh) 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
US20230167159A1 (en) 2020-03-20 2023-06-01 Kansas State University Research Foundation Sars-coronavirus 2 (sars-cov-2) subunit vaccine candidates
US20240210415A1 (en) 2020-03-24 2024-06-27 Icahn School Of Medicine At Mount Sinai Recombinant sars-cov-2 spike protein and uses thereof
GB202004493D0 (en) 2020-03-27 2020-05-13 Imp College Innovations Ltd Coronavirus vaccine
WO2021200800A1 (ja) 2020-03-30 2021-10-07 国立大学法人大阪大学 コロナウイルス感染またはコロナウイルス感染に伴う症状の予防または治療ワクチン
US11278617B2 (en) 2020-03-31 2022-03-22 Engimata, Inc Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
WO2021201612A1 (ko) 2020-03-31 2021-10-07 주식회사 에스엘백시젠 신규 코로나바이러스 예방 및 치료용 백신 조성물
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
US20230226169A1 (en) 2020-04-01 2023-07-20 University Of Florida Research Foundation Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
WO2021202599A2 (en) 2020-04-01 2021-10-07 Valiant Biosciences, Llc Adeno-associated virus based compositions and related methods for inducing humoral immunity
CA3179038A1 (en) 2020-04-01 2021-10-07 Diosynvax Ltd Coronavirus vaccines
TW202202169A (zh) 2020-04-02 2022-01-16 中央研究院 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法
WO2021203044A2 (en) 2020-04-03 2021-10-07 Icahn School Of Medicine At Mount Sinai High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2
CN111139241B (zh) 2020-04-03 2020-09-01 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
KR20230017373A (ko) 2020-04-03 2023-02-03 펩티씨 백신즈 리미티드 코로나바이러스 백신
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
RU2747762C1 (ru) 2020-04-05 2021-05-13 Илья Владимирович Духовлинов Вакцина для профилактики или лечения коронавирусной инфекции на основе генетической конструкции
US20230321218A1 (en) 2020-04-07 2023-10-12 Ramot At Tel-Aviv University Ltd. Sars-cov2 coronavirus reconstituted rbm and uses thereof
CN112023035A (zh) 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
US20230310582A1 (en) 2020-04-14 2023-10-05 Duke University Sars-2 spike protein designs, compositions and methods for their use
WO2021211760A1 (en) 2020-04-14 2021-10-21 The Regents Of The University Of California Large sequence pan-coronavirus vaccine compositions
US20230146256A1 (en) 2020-04-17 2023-05-11 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
JP2023522126A (ja) 2020-04-20 2023-05-26 エヌイーシー オンコイミュニティ エーエス ＳＡＲＳ－ＣｏＶ－２ワクチン
CA3176416A1 (en) 2020-04-21 2021-10-28 Modassir CHOUDHRY Cellular vaccine platform and methods of use
WO2021216738A2 (en) 2020-04-21 2021-10-28 Intima Bioscience, Inc. Compositions and methods of generating an immune response
US20230143228A1 (en) 2020-04-21 2023-05-11 Emory University Coronavirus vaccines, compositions, and methods related thereto
WO2021212568A1 (zh) 2020-04-21 2021-10-28 苏州方科生物科技有限公司 新型冠状病毒特异性抗原肽及其用途
AU2021261471B2 (en) 2020-04-22 2024-10-24 BioNTech SE Coronavirus vaccine
CA3176481A1 (en) 2020-04-22 2021-10-28 Marjoh NAUTA Coronavirus vaccine
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
KR102482994B1 (ko) 2020-04-29 2022-12-29 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
IT202000009625A1 (it) 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.
WO2021223647A1 (en) 2020-05-06 2021-11-11 The University Of Hong Kong Compositions and methods for making and using vaccines against covid-19
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
WO2021224946A1 (en) 2020-05-07 2021-11-11 Bharat Biotech International Limited Coronavirus vaccine through nasal immunization
CN112695057B (zh) 2020-05-11 2022-04-26 广东珩达生物医药科技有限公司 Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
EP4105228A4 (en) 2020-05-11 2023-10-11 Hengda Biomedical Technology Co., Ltd. SARS-COV-2 ANTIGEN POLYPEPTIDE, RECOMBINANT ADENO-ASSOCIATED VIRUS THEREOF AND APPLICATION IN THE PRODUCTION OF A VACCINE
WO2021231560A1 (en) 2020-05-12 2021-11-18 Greffex, Inc. Engineering coronavirus spike proteins as vaccine antigens, their design and uses
US20230181481A1 (en) 2020-05-15 2023-06-15 Modernatx, Inc. Rna formulations for high volume distribution, and methods of using the same for treating covid-19
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
US12331078B2 (en) 2020-05-18 2025-06-17 The Regents Of The University Of Colorado, A Body Corporate Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
CN111363858B (zh) 2020-05-26 2020-09-29 南京黎明生物制品有限公司 2019-nCoV S基因检测核酸组合物及试剂盒与生产方法
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
WO2021253172A1 (zh) 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
WO2022003119A1 (en) 2020-07-01 2022-01-06 CEBINA GmbH Cross-reactive coronavirus vaccine
WO2022000845A1 (zh) 2020-07-01 2022-01-06 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种预防SARS-CoV-2的重组蛋白疫苗及其制备方法
WO2022006565A1 (en) 2020-07-03 2022-01-06 Kang Zhang Polypeptides, vaccine compositions, and use thereof for inducing immune response to sars-cov-2 in primates
GB2596820A (en) 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
US20230248818A1 (en) 2020-07-08 2023-08-10 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2
CN111978377B (zh) 2020-07-09 2022-05-31 苏州和锐生物科技有限公司 Covid-19抗原、制备方法和应用
WO2022011332A2 (en) 2020-07-10 2022-01-13 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
CN112043825B (zh) 2020-07-13 2023-12-05 中国医学科学院医学生物学研究所 一种基于新型冠状病毒突刺蛋白s1区域预防新型冠状病毒感染的亚单位疫苗
CN111848753B (zh) 2020-07-20 2022-03-15 中国科学院过程工程研究所 新型冠状病毒抗原表位及其应用
RU2733834C1 (ru) 2020-07-28 2020-10-07 Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
CN112028976A (zh) 2020-08-05 2020-12-04 上海裕隆生物科技有限公司 2019新型冠状病毒刺突蛋白受体结合结构域蛋白及应用
CN111939250B (zh) 2020-08-17 2022-07-29 郑州大学 一种预防covid-19的疫苗及其制备方法
RU2731356C9 (ru) 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
RU2731342C9 (ru) 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN112048005B (zh) 2020-09-04 2022-09-09 江苏省中国科学院植物研究所 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物
CN112094327A (zh) 2020-09-25 2020-12-18 军事科学院军事医学研究院军事兽医研究所 基于新型冠状病毒rbd-sd1蛋白的截短体及其应用
CN112266411B (zh) 2020-09-25 2022-06-24 北京诺思兰德生物技术股份有限公司 一种新型冠状病毒疫苗及其应用
CN112226445B (zh) 2020-10-20 2021-05-11 成都欧林生物科技股份有限公司 编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
EP4234585A4 (en) 2020-10-23 2024-10-02 Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) FUSION PROTEIN AND ITS APPLICATION
CN112220920B (zh) 2020-10-30 2023-06-13 上海泽润生物科技有限公司 一种重组新型冠状病毒疫苗组合物
CN112358533B (zh) 2020-10-30 2023-07-14 上海泽润生物科技有限公司 重组刺突蛋白及其制备方法和用途
US20240041785A1 (en) 2020-11-16 2024-02-08 BioNTech SE Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
CN114517205A (zh) 2020-11-20 2022-05-20 北京震旦鼎泰生物科技有限公司 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用
CN112480217B (zh) 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CN112626089B (zh) 2020-12-08 2022-03-11 杭州百凌生物科技有限公司 一种SARS-CoV-2病毒S蛋白受体结合区域编码基因、抗体及应用
BR112023012303A2 (pt) 2020-12-22 2024-02-15 CureVac SE Vacina de rna contra variantes de sars-cov-2
CN112794884B (zh) 2020-12-28 2022-02-18 中国科学院微生物研究所 新型冠状病毒蛋白、制备方法及中和抗体检测试剂盒
CN112321688B (zh) 2021-01-06 2021-03-26 广东华南疫苗股份有限公司 稳定的冠状病毒重组蛋白二聚体及其表达载体
US20240299531A1 (en) 2021-03-15 2024-09-12 Moderna TX, Inc Therapeutic use of sars-cov-2 mrna domain vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070626A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Respiratory virus vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Lan, J. et al., "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor", Nature, Vol. 581, 30 March 2020, Pages 215–220. *

Also Published As

Publication number Publication date
JP2025063030A (ja) 2025-04-15
BR112022019782A2 (pt) 2022-12-13
EP4138897A1 (en) 2023-03-01
GB202307565D0 (en) 2023-07-05
KR20230015350A (ko) 2023-01-31
CN116585464A (zh) 2023-08-15
GB2594365B (en) 2023-07-05
US11925694B2 (en) 2024-03-12
US20240390524A1 (en) 2024-11-28
CA3173922A1 (en) 2021-10-28
GB202105481D0 (en) 2021-06-02
CN115867654A (zh) 2023-03-28
GB2594364A (en) 2021-10-27
WO2021214204A1 (en) 2021-10-28
AU2025200483A1 (en) 2025-02-20
KR20230004735A (ko) 2023-01-06
CN115811986A (zh) 2023-03-17
IL297419A (en) 2022-12-01
US20230075979A1 (en) 2023-03-09
MX2024011779A (es) 2024-11-08
EP4549449A3 (en) 2025-08-13
US20220249704A1 (en) 2022-08-11
MX2022013254A (es) 2023-01-24
AU2021260099A1 (en) 2022-11-24
CA3174215A1 (en) 2021-10-28
KR102796212B1 (ko) 2025-04-17
AU2021261471B2 (en) 2024-10-24
EP4139452A1 (en) 2023-03-01
ZA202210526B (en) 2025-01-29
ZA202210524B (en) 2024-07-31
IL317516A (en) 2025-02-01
US20230073461A1 (en) 2023-03-09
JP2023522246A (ja) 2023-05-29
JP2023522249A (ja) 2023-05-29
MX2022013255A (es) 2023-01-24
EP3901260A1 (en) 2021-10-27
US11779659B2 (en) 2023-10-10
GB202105465D0 (en) 2021-06-02
EP4549449A2 (en) 2025-05-07
CN118121722A (zh) 2024-06-04
EP4592306A3 (en) 2025-10-08
CN113521269A (zh) 2021-10-22
AU2021261471A1 (en) 2022-11-17
KR102813425B1 (ko) 2025-05-28
JP2021191743A (ja) 2021-12-16
IL297419B2 (en) 2025-02-01
IL297419B1 (en) 2024-10-01
BR112022019781A2 (pt) 2022-12-13
EP4592306A2 (en) 2025-07-30
US20240075165A1 (en) 2024-03-07
JP7514206B2 (ja) 2024-07-10
IL315928A (en) 2024-11-01
JP2021185136A (ja) 2021-12-09
US11951185B2 (en) 2024-04-09
US20220273820A1 (en) 2022-09-01
GB2594365A (en) 2021-10-27
US20250242059A1 (en) 2025-07-31
IL315743A (en) 2024-11-01
MX2024009072A (es) 2024-07-30
US12133899B2 (en) 2024-11-05
CN113521268A (zh) 2021-10-22
EP3901261A1 (en) 2021-10-27
CN118490818A (zh) 2024-08-16
IL297417B1 (en) 2025-02-01
WO2021213924A1 (en) 2021-10-28
JP7604519B2 (ja) 2024-12-23
AU2021260099B2 (en) 2025-05-22
IL297417B2 (en) 2025-06-01
US11547673B1 (en) 2023-01-10
IL297417A (en) 2022-12-01
TW202508622A (zh) 2025-03-01
TW202206096A (zh) 2022-02-16

Similar Documents

Publication Publication Date Title
TWI860474B (zh) 冠狀病毒疫苗
US20240002127A1 (en) Coronavirus vaccine
JP2023081859A (ja) コロナウイルスワクチン
RU2849033C1 (ru) Вакцина против коронавируса
HK40061535A (en) Coronavirus vaccine
HK40061540A (en) Coronavirus vaccine
HK40061483A (en) Coronavirus vaccine
HK40061489A (zh) 冠状病毒疫苗
HK40092713A (zh) 冠状病毒疫苗
HK40063946A (en) Coronavirus vaccine
HK40091203A (zh) 冠状病毒疫苗